Publication AWA
At the Public Information Bulletin of the Agency for Health Technology Assessment and Tarification (AWA) has published reviews analyses for the evaluation of reimbursement applications:
- Rystiggo (rozanolixizumab) for the treatment of patients with generalized myasthenia gravis
- Calquence (acalabrutinib) for the treatment of patients with B-cell lymphomas
- Capvaxive, pneumococcal vaccine, polysaccharide, 21-valent conjugate, indicated for the prevention of pneumococcal infections in adults over 65 years of age
- Akantior (polihexanidum) for the treatment of patients with acanthamoeba keratitis
We encourage you to read the full documents and submit comments within the prescribed period of 7 days from the date of publication.
